An observational study in Pancreatic Cystic Lesion, sponsored by Société Française d'Endoscopie Digestive. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-02.
Sponsored by Société Française d'Endoscopie Digestive · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Large prospective comparative observational study in numerous reference centers in France, comparing infectious complications in patients admitted for pancreatic cystic lesions (PCL) aspiration performed with or without antibiotic prophylaxis (ATBp) according to the usual practices.
This is a prospective, comparative, observational, multicenter study, with the primary objective of comparing the infection rates in pancreatic cystic lesions (PCL) aspirated under EUS, with and without the administration of ATBp.
A sample size of 1702 patients will be needed over a 3-year study period.
The complication rate after EUS fine needle aspiration (EUS-FNA) for pancreatic cystic lesions (PCL) is low, around 1-3% according to various series. However, it has long been recommended to perform this procedure under antibiotic prophylaxis (ATBp). Due to the risk of developing resistance to certain classes of antibiotics and the risk of complications, particularly allergic reactions, the role of ATBp in this indication needs to be reconsidered. The latest recommendations from European and French societies do not support the systematic formal indication of ATBp for aspiration under EUS. Because the literature on the subject is sparse and equivocal, practices remain varied (some performing PCL aspirations with and others without ATBp), and scientific societies do not provide a formal stance on the benefit of such ATBp. Therefore, we decided to conduct a very large prospective comparative observational study in numerous reference centers in France (centers of the Research and Action Group in Endoscopy - GRAPHE), comparing infectious complications in patients admitted for EUS-FNA for PCL performed with or without ATBp according to the usual practices .
This is a prospective, comparative, observational, multicenter study.
Primary objective:
Comparison of infection rates after EUS-FNA for pancreatic cystic lesions (PCL) , with and without the administration of ATBp.
Secondary objectives:
Rates of other infectious complications (pulmonary, urinary, etc.) Rates of post-ATBp complications, particularly allergic reactions Prolongation of scheduled hospitalization Evaluation of factors associated with post-EUS aspiration infection of PCL
After the endoscopic exploration, the patient will be monitored for the potential occurrence of complications related to EUS (perforation, hemorrhage, infection, allergy, etc.). Any adverse events will be recorded at 30 days post-procedure.
A sample size of 1702 patients will be needed over a 3-year study period.
Société Française d'Endoscopie Digestive is the lead sponsor of 25 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with pancreatic cystic lesions for whom an EUS-FNA is indicated
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergoing EUS-FNA for pancreatic cystic lesions WITH ATBp
Procedure: EUS-FNA · Drug: ATBp
Patients undergoing EUS-FNA for pancreatic cystic lesions without ATBp
Procedure: EUS-FNA
Puncture of pancreatic cystic lesion with a fine needle under EUS guidance
Also known as: EUS fine needle aspiration
Antibiotic prophylaxis consists of a single intravenous administration before or at the beginning of the procedure according to the common practices of each practitioner or unit
Also known as: Antibiotic prophylaxis
Post EUS-FNA PCL infection rate
Post-EUS-FNA infection rate of PCL (patients exhibiting clinical and biological signs - fever \>38.5°C, neutrophilic leukocytosis, elevated CRP, pathogen identification in blood cultures - indicative of sepsis requiring prolonged antibiotic therapy). The occurrence of the aforementioned clinical and biological signs, along with imaging evidence (such as cyst wall thickening or presence of intracystic air images) and the absence of another infection source (urinary, pulmonary, venous, etc.) will lead to the diagnosis of post-FNA infection. Centralized validation of infection cases will be conducted by an expert panel based on clinical, biological, and imaging findings.
Time frame: 30 days
Rate of urinary infectious complications
Number of patients with at least one urinary infection within 21-30 days after EUS-FNA
Time frame: 30 days
Rate of post-ATBp allergic reactions
Number of patients with at least one allergic reaction within 21-30 days after EUS-FNA
Time frame: 30 days
Duration and extension of hospitalization
Number of hospitalization days per stay within 30 days following EUS-FNA
Time frame: 30 days
Diameter of the needle used for EUS-FNA
25G, 22G, 20G, or 19G
Time frame: 1 days
Associated procedures (confocal endomicroscopy or intracystic biopsy)
Yes or No
Time frame: 1 days
Appearance of the fluid
Thin, thick, hemorrhagic
Time frame: 1 day
Complete aspiration of the cyst fluid
Yes or No
Time frame: 1 day
Nature of the PCL
mucinous vs. non-mucinous
Time frame: 30 days
Age
Years
Time frame: 1 day
Gender
Male or female
Time frame: 1 day
Diabetes
Yes or No
Time frame: 1 day
Immunosuppression
Yes or No
Time frame: 1 day
BMI
Weight/(size)2 expressed in in kg/m\^2
Time frame: 1 day
history of aspiration of the same lesion
Yes or No
Time frame: 1 day
Rate of pulmonary infectious complications
Number of patients with at least one pulmonary infection within 21-30 days after EUS-FNA
Time frame: 30 days
Plan to share: No
Start is estimated for Sep 2024; primary completion for Sep 2027, 36 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Société Française d'Endoscopie Digestive